BiotechTV

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Stifel Financial Corp. analyst Alex Thompson, PhD joins BiotechTV for Analyst Thursdays and talks I&I ahead of the July 4th holiday He gives his general take on I&I and comments on argenx, Immunovant, Ascendis, Celldex, Third Harmonic, Apogee, Spyre, Viridian, Dianthus, AnaptysBio, and Pliant. Full video: https://lnkd.in/gFFF5uDX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Mereo BioPharma's CEO Denise Scots-Knight discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat. She describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the clinical benefit to patients’ lives. Plus, the role that the company’s alvelestat program could play in lung conditions. Full video: https://lnkd.in/g7Rj336i BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: QIAGEN's CEO Thierry BERNARD describes the latest sample, assay, and bioinformatics technologies that are powering life sciences and molecular diagnostics. He describes the scientific advances underlying QIAGEN's four business pillars: sample technologies, diagnostic solutions, PCR, and genomics / next-generation sequencing. Full video: https://lnkd.in/gAKWgWuq BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Disc Medicine's CEO John Quisel reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program. He describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light. Plus, learnings about clinical endpoints from the company's P2 experience, and highlights on two hepcidin programs. Full video: https://lnkd.in/gAeE5uUc BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐒𝐩𝐢𝐧𝐚𝐥 𝐂𝐨𝐫𝐝 𝐈𝐧𝐣𝐮𝐫𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: Axonis Therapeutics' CEO Joanna Stanicka discusses the importance of KCC2 inhibition in CNS disorders. She describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that KCC2 inhibition plays in neuronal function. Full video: https://lnkd.in/gCcbGZxM BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐒𝐩𝐢𝐧𝐚𝐥 𝐂𝐨𝐫𝐝 𝐈𝐧𝐣𝐮𝐫𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: Ilan Zipkin, a venture partner at Breakout Ventures, describes what he looks for when investing in the spinal cord injury space. He says his firm looks at how cell therapies can be augmented with other technologies to help them succeed. Full video: https://lnkd.in/gTmuxgU4 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐒𝐩𝐢𝐧𝐚𝐥 𝐂𝐨𝐫𝐝 𝐈𝐧𝐣𝐮𝐫𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: SCI Ventures is philanthropic but has been designed to invest in spinal cord injuries like a VC fund. Founding Managing Director Adrien Cohen describes how this $30M fund has been structured, what typical investments will look like, and how he hopes it will grow over time. Full video: https://lnkd.in/gQCZeH9u BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐒𝐩𝐢𝐧𝐚𝐥 𝐂𝐨𝐫𝐝 𝐈𝐧𝐣𝐮𝐫𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: University of Miami Miller School of Medicine's Jim Guest on recent advances, and clinical trial design best practices for spinal cord injury. He describes a recent clinical trial success using electrical stimulation of the cervical spinal cord, and also discusses best practices for conducting clinical trials, including patient consent. Full video: https://lnkd.in/gyJTHzTE BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐒𝐩𝐢𝐧𝐚𝐥 𝐂𝐨𝐫𝐝 𝐈𝐧𝐣𝐮𝐫𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦: NeuroHagana Co-Founder and CEO Angela Ruban discusses the role that glutamate excitotoxicity plays in neurotrama injury. She describes how her company NeuroHagana is developing a treatment to lower blood glutamate levels that she believes would ideally be administered as quickly after acute injury as possible. Full video: https://lnkd.in/gjQnGEV6 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Baird's Brian Skorney, CFA joins BiotechTV for Analyst Thursdays and breaks down the Sarepta approval and more. He gives his take on biotech and discusses Sarepta, Lexeo, Gilead, Mirum, Amgen, Vertex, Neurocrine, and Applied Therapeutics. Full video: https://lnkd.in/gG-HJhWj BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent